Glaukos Corporation Stock News

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

First Trust Advisors LP grew its stake in shares of Glaukos Co. (NYSE:GKOS) by 20.7% in the 2nd quarter, Holdings Channel reports. The firm owned 41,596 shares of the medical instruments suppliers stock after acquiring an additional 7,134 shares during the quarter. First Trust Advisors LPs holdings in Glaukos were worth $3,529,000 as of its []

Schonfeld Strategic Advisors LLC acquired a new position in shares of Glaukos Co. (NYSE:GKOS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,307 shares of the medical instruments suppliers stock, valued at approximately $281,000. A number of other []

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2021 Results - Earnings Call Transcript

CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos.

Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Glaukos Corp (NYSE:GKOS) has settled a patent infringement lawsuit with Ivantis Inc. The lawsuit was initiated by Glaukos in 2018 in the U.S. District Court for the Central District of California,

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content:   William Blair Down

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal d

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Glaukos Corporation's (GKOS) CEO Tom Burns on Q2 2021 Results - Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS) posted a second-quarter adjusted EPS loss of $(0.11), ahead of $(0.28) consensus, and better than $(0.61) a year ago. Sales increased from $31.6 million to $78.1 mil